

Pembrolizumab KEYNOTE-158

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-158

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic small intestine cancer, who have disease progression on or following at least one prior therapy.

Experimental Arm: Pembrolizumab

Control Arm: Single arm cohort study (Phase II)



